Reaction

Tumour Fistulisation reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 60 reports · 1 co-occurring drugs

As of the last recalculation, Tumour Fistulisation appears in 60 FAERS reports alongside 1 co-occurring drug terms. The strongest observed disproportionality signal is ATEZOLIZUMAB (PRR 133.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Atezolizumab12133.7133.8

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.